The state of Florida currently has 32 active clinical trials seeking participants for Ulcerative Colitis research studies. These trials are conducted in various cities, including Miami, Tampa, Jacksonville and Orlando.
A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Vixarelimab in Participants With Moderate to Severe Ulcerative Colitis (UC)
NCT06137183
Recruiting
The purpose of this study is to evaluate the efficacy, safety, and pharmacokinetics of vixarelimab compared with placebo in participants with moderate to severe UC who have demonstrated inadequate response to, loss of response to, or intolerance to prior conventional or advanced therapy.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/15/2024
Locations: Orlando Gastroenterology, P.A., Orlando, Florida +1 locations
Conditions: Ulcerative Colitis
Register for Updates
Treat-to-Target of Endoscopic Remission in Patients With IBD in Symptomatic Remission
NCT05230173
Recruiting
The purpose of this study is to compare the effectiveness and safety of a strategy of switching to an alternative targeted immunomodulator (TIM) therapy to treat to a target of endoscopic remission, versus continuing index TIM in patients with inflammatory bowel disease (IBD) (Crohn's disease or ulcerative colitis [UC]) in symptomatic remission with moderate to severe endoscopic inflammation despite optimization of index TIM in a real-world setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
04/12/2024
Locations: Mayo Clinic Jacksonville, Jacksonville, Florida
Conditions: Ulcerative Colitis, Crohn Disease
Register for Updates
Hyperbaric Oxygen Therapy for Ulcerative Colitis
NCT05987852
Recruiting
Chronic intestinal hypoxia and accompanying mucosal inflammation is a hallmark of ulcerative colitis (UC). Hyperbaric oxygen therapy (HBOT) involves breathing 100% oxygen under increased atmospheric pressure to increase tissue oxygenation. Two small prospective randomized controlled trials have demonstrated that the delivery of HBOT to UC patients hospitalized for acute moderate to severe flares results in improved remission rates and avoidance of in-hospital progression to biologics, small mole... Read More
Gender:
All
Ages:
Between 18 years and 85 years
Trial Updated:
04/12/2024
Locations: University of Miami Health, Miami, Florida +1 locations
Conditions: Ulcerative Colitis
Register for Updates
Study of Tilpisertib Fosmecarbil in Participants With Moderately to Severely Active Ulcerative Colitis
NCT06029972
Recruiting
The goal of this study is to learn if tilpisertib fosmecarbil (formerly known as GS-5290) is effective and safe in treating participants with moderate to severe ulcerative colitis. The study will compare participants in different treatment groups treated with tilpisertib fosmecarbil with participants treated with placebo. The primary objective of this study is to demonstrate the efficacy of tilpisertib fosmecarbil, compared to placebo control, in achieving Clinical Response at Week 12.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
04/09/2024
Locations: Encore Medical Research, LLC, Hollywood, Florida +6 locations
Conditions: Ulcerative Colitis
Register for Updates
A Phase 1b Proof-of-concept Trial Exploring the Effects of FE 999322 and FE 999324 in Adults With Mild to Moderate Ulcerative Colitis
NCT06260267
Recruiting
To explore the safety of FE 999322 (microbiota suspension) and FE 999324 (microbiota capsule) versus placebo in subjects with active mild to moderate ulcerative colitis (UC).
Gender:
All
Ages:
18 years and above
Trial Updated:
04/03/2024
Locations: Ferring Investigational Site, Jacksonville, Florida
Conditions: Ulcerative Colitis
Register for Updates
An Extension Study for Treatment of Moderately to Severely Active Ulcerative Colitis
NCT03950232
Recruiting
The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely active ulcerative colitis (UC) who previously received double-blind treatment (either etrasimod 2 mg per day or placebo) during participation in one of the qualified Phase 3 or Phase 2 double-blind, placebo-controlled parent studies including but not limited to: (APD334-301 [NCT03945188] or APD334-302 [NCT03996369] or APD334-210 [NCT04607837]).
Gender:
All
Ages:
Between 16 years and 80 years
Trial Updated:
04/02/2024
Locations: Bay Area Chest Physicians, P.A.,-(Pulmonary Function Test), Clearwater, Florida +43 locations
Conditions: Ulcerative Colitis
Register for Updates
A Study to Evaluate Etrasimod Treatment in Adolescents With Ulcerative Colitis
NCT05287126
Recruiting
The purpose of this study is to determine the safety, efficacy, and pharmacokinetics (PK) of etrasimod for the treatment of moderately to severely active ulcerative colitis in adolescents (≥ 12 years up to < 18 years of age). Participants who will complete the total 52-week treatment period will have the opportunity to continue in a Long-Term Extension (LTE) Period of up to 4 years (5 years after study enrollment), or until marketing authorization is obtained in the participant's country, whiche... Read More
Gender:
All
Ages:
Between 12 years and 17 years
Trial Updated:
04/02/2024
Locations: IHS Health Research, Kissimmee, Florida +3 locations
Conditions: Ulcerative Colitis
Register for Updates
VE202 in Patients With Mild-to-Moderate Ulcerative Colitis
NCT05370885
Recruiting
A Phase 2 study to evaluate the safety, efficacy, and microbiota changes of VE202 in patients with mild to moderate ulcerative colitis (UC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/29/2024
Locations: University of Miami, Miami, Florida +4 locations
Conditions: Ulcerative Colitis, Colitis, Ulcerative
Register for Updates
Long-term Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05672199
Recruiting
The primary objective of this study is to evaluate the long-term safety and tolerability of efavaleukin alfa in participants with moderate to severe ulcerative colitis (UC).
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/13/2024
Locations: Indian Health Service Health Research, Kissimmee, Florida
Conditions: Ulcerative Colitis
Register for Updates
Study to Evaluate the Clinical Activity and Safety of Oral NX-13 in Moderate to Severe Ulcerative Colitis
NCT05785715
Recruiting
Phase 2 induction study with a long-term extension (LTE) period in participants with moderate to severe ulcerative colitis (UC).
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/13/2024
Locations: Orlando Health, Inc., Orlando, Florida +1 locations
Conditions: Ulcerative Colitis
Register for Updates
Study of ABBV-668 Oral Capsules to Assess Adverse Events and Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis
NCT05570006
Recruiting
Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large intestine). This study will assess how safe and effective ABBV-668 is in treating adult participants with UC. Adverse events and change in disease activity will be assessed. ABBV-668 is an investigational drug being developed for the treatment of moderate to severe UC. Approximately 40 adult participants diagnosed with UC will be enrolled in approx... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Ctr for Advanced Gastroenterol /ID# 249226, Maitland, Florida +2 locations
Conditions: Ulcerative Colitis
Register for Updates
A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis
NCT05767021
Recruiting
A study to investigate bowel urgency in adults with moderately to severely active ulcerative colitis (UC) treated with mirikizumab. The study will have 4 periods and will last for 36 weeks.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/07/2024
Locations: Central Florida Gastro Research, Clearwater, Florida +8 locations
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic
Register for Updates